摘要
目的:观察奥氮平(欧兰宁)合用碳酸锂缓释片与单用奥氮平(欧兰宁)治疗伴攻击行为的精神分裂症的疗效与不良反应。方法:60例伴有攻击行为的精神分裂症住院患者随机分为奥氮平合用碳酸锂缓释片组(研究组)30例和单用奥氮平组(对照组)30例,治疗12周。分别在治疗前及治疗后第2、4、6、8周末,应用阳性和阴性症状量表(PANSS)评定疗效,用TESS量表评定不良反应。结果:研究组PANSS评分(包括兴奋症状分及攻击因子分)改善明显优于对照组(P<0.05)。研究组与对照组不良反应无明显差异。结论:奥氮平合用碳酸锂缓释片治疗伴攻击行为的精神分裂症的疗效肯定,安全性与耐受性较好。
Objective：the concept olanzapine combination of lithium carbonate with olanzapine in the treatment of schizophrenia associated with aggressive behavior and adverse reactions. Methods：60 patients with aggressive behavior in hospitalized patients with schizophrenia were randomly divided into 30 cases olanzapine combination of lithium carbonate group（study group） and with Austrian olanzapine group （control group）, 30 cases, 12 weeks of treatment. The 2,4,6,8 weekend before treatment and after treatment, the application of positive and negative syndrome scale （PANSS）to assess the clinical assessment of adverse reactions with TESS Scale. Results： The study group PANSS score （including excited the symptoms points and attack factor scores） improved significantly better than the control group （P〈0.05）.Study group and the control group, no significant difference in adverse reactions.Conclusion： olanzapine combination of the efficacy of lithium in the treatment of schizophrenia associated with aggressive behavior is certainly better safety and tolerability.
出处
《北方药学》
2012年第12期12-13,共2页
Journal of North Pharmacy
